Fujifilm Announces Financial Results for the First Quarter Ended June 30, 2026

TOKYO, August 6, 2026 – FUJIFILM Holdings Corporation announced today its financial results for the first quarter, which ended June 30, 2026.

• Revenue was JPY826.5 billion and increased 10.3% year-over-year.
• Operating income was JPY51.2 billion and decreased 32.0% year-over-year, broadly in line with the internal plan.
• Net income attributable to FUJIFILM Holdings was JPY37.4 billion and decreased 30.4% year‑over‑year.

• For the fiscal year ending March 2027, the company projects record-high financial performance, with revenue of JPY3.56 trillion, reflecting strong sales in the Electronics segment and favorable foreign exchange impacts.
• Operating income is expected to reach JPY365.0 billion, in line with the previous forecast, as increased profits in the Electronics segment are expected to be offset by delays in the ramp-up of Bio CDMO facilities and the impact of rising semiconductor memory prices.
• Net income attributable to FUJIFILM Holdings is forecasted at JPY280.0 billion.

Revenue increased to a record high, driven by strong performance particularly in semiconductor materials and data tapes in the Electronic segment. While increased costs in Bio CDMO, one-time expenses related to strengthening the operational foundation of the Business Innovation, and higher raw material prices created headwinds for profitability, the Company revised its revenue forecast upward from the previous outlook, reflecting strong business performance.

“While reported operating income was affected by higher costs and one-time expenses, underlying performance remained broadly in line with our expectations. Supported by the strength of our growth businesses and continued expansion of demand, we have revised our revenue forecast upward and remain confident in our long-term growth trajectory,” says Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Holdings Corporation.

• Revenue increased by 12.4% year-over-year to JPY256.8 billion, while operating income declined to a loss of JPY12.7 billion, primarily due to the increased cost in Bio CDMO and higher raw material costs due to surging silver prices.
• In the Medical Systems business, the company maintained strong growth, supported by increased sales in Japan and China in addition to major markets such as the United States and Europe. Higher sales of Healthcare IT solutions also contributed to revenue growth.
• In the Bio CDMO business, revenue grew by more than 6%, driven by the ramp-up of new large-scale facilities and the absence of the planned facility shutdowns that occurred in the previous fiscal year. In contrast, revenue from small- and medium-scale facilities declined due to unplanned shutdowns associated with regulatory inspections and the absence of cancellation fees recorded in the previous fiscal year.
• In the LS Solutions business, revenue increased, driven by expanded use of cell culture media among major pharmaceutical companies.

• Revenue increased by 25.0% year-over-year to JPY127.7 billion, and operating income rose by 38.2% year-over-year to JPY31.1 billion.
• In the Electronic Materials business, revenue increased, supported by strong sales of the world's leading CMP slurries for copper interconnects and NTI developers, together with solid sales of liquid polyimides for advanced semiconductor packaging applications.
• In the Advanced Functional Materials business, revenue increased, supported by higher sales of data tapes to major IT companies.

• Revenue decreased by 0.1% year-over-year to JPY273.2 billion, and operating income declined to a loss of JPY17.0 billion.
• In the Business Solutions business, revenue increased, driven by higher sales in overseas enterprise system sales and implementation support services.
• In the Office Solutions business, revenue declined due to lower exports to Europe and North America and reduced demand for equipment replacements in China.
• In the Graphic Communications business, revenue increased due to strong sales of inkjet printheads.

• Revenue increased by 16.2% year-over-year to JPY168.8 billion, and operating income rose by 3.9% year-over-year to JPY43.4 billion. 
• In the Consumer Imaging business, revenue increased due to strong sales of instax^™ products, supported by robust demand for mid- to high-end models such as the instax mini Evo^™ and instax WIDE 400^™, coupled with the successful launch of the new entry-level instax mini 13^™, and increased supply following capacity expansion for instax^™ film production.
• In the Professional Imaging business, revenue increased, driven by strong sales of key models including the X-T30 III and X-E5, as well as continued strong demand for long-selling products such as the X100VI.

For more details, please visit the Investor Relations section of Fujifilm website

• * Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.